This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SRSF3 · Western blot design guide
SRSF3 Western Blot Planning Guide
Plan a SRSF3 Western blot around the catalog-observed 19.3 kDa band, image-backed PB9509 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
SRSF3 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 19.3 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 15% | |
| Positive control | Adipose tissue | |
| Negative control | Target knockdown/knockout |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 19.3 kDa |
| ⓘ | Localization | Nucleus / Nucleus speckle |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated SRSF3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.2 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9509 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected SRSF3 Western Blot Band Size?
Use the product-observed 19.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 19.3 kDa | Matches the authoritative product WB observation. |
| 19.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected SRSF3 appearancePlan around 19.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 19.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 19.3 kDa from UniProt P84103; retain as context. |
| Gel selection | 15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9509. |
| Situation | Likely cause | Next action |
|---|---|---|
| 19.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing SRSF3 band
PB9509 · SRSF3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SRSF3 Western blot
🧪Use Adipose tissue as the first positive-control candidate; no defensible HPA Not detected tissue was available, so use a target knockdown/knockout negative control.
Positive control: Adipose tissue (High)
Negative control: Target knockdown/knockout
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for SRSF3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|
Section 3
Advanced SRSF3 Western Blot Tips
Deeper troubleshooting and optimisation questions for SRSF3, answered from its protein features.
Which band should guide the blot?
Use 19.3 kDa, the observation attached to the authoritative PB9509 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 19.3 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use a target knockdown/knockout control when no HPA Not detected tissue is available.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SRSF3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9509 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
SRSF3 Western Blot Reagents
Human-reactive SRSF3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-SFRS3/SRSF3 Antibody Picoband®
Cat # PB9509
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P84103
- Human Protein Atlas — SRSF3
- PB9509 product record
- PMC5081167 — The High Level of Aberrant Splicing of ISCU in Slow-Twitch Muscle May Involve the Splicing Factor SRSF3 (PloS one, 2016)
- PMC12709111 — [Molecular Mechanisms of Intervention With Lishukang Capsule in a Rat Model of High-Altitude Pulmonary Edema] (Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025)
- PMC4648679 — Construction and evaluation of an adenoviral vector for the liver-specific expression of the serine/arginine-rich splicing factor, SRSF3 (Plasmid, 2015)